New pill shows promise for controlling blood pressure in rare hormone disorder
NCT ID NCT04605549
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called CIN-107 in 15 adults with primary aldosteronism, a condition where the body makes too much of a hormone that raises blood pressure. Participants took the drug once daily for up to 12 weeks to see if it safely lowered blood pressure. The goal was to find a better way to manage this condition.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- CIN-107 (a drug taken as a tablet once daily)
- What this could lead to
- If it works, this could provide a new treatment option for people with primary aldosteronism to better control their blood pressure.
- What could go wrong
- This was a small, early-phase study with only 15 participants, so results may not apply to everyone. The drug may cause side effects or not work as well in larger, longer trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
15 people
The number who actually took part.
- Started
-
Mar 2021
- Finished
-
Oct 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 130 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Have been diagnosed with PA. 2. Are taking mineralocorticoid receptor antagonist (MRA) to control BP; or are newly diagnosed with PA and have not started MRA treatment. 3. Are willing and able to cease dosing of MRA for up to 4 weeks in patients taking MRA. 4. Are willing to be compliant with the contraception and reproduction restrictions of the study. 5. Have increased SBP by ≥ 20 mmHg or have SBP ≥ 160 mmHg after dosing of MRA treatment is ceased for up to 4 weeks duration, or have SBP ≥ 150 mmHg for patients who are newly diagnosed with PA and have not taken an MRA in the past 12 weeks. Exclusion Criteria: 1. At Screening Visit, have a single occurrence of mean seated SBP \> 180 mmHg or DBP \> 110 mmHg if not taking an MRA; or have a mean seated SBP ≥ 160 mmHg or DBP ≥ 100 mmHg if currently taking an MRA. 2. Have a body mass index \> 45 kg/m2. 3. Have had a previous surgical intervention for an adrenal adenoma or have a planned adrenal carcinoma, adrenalectomy, renal nerve denervation, or adrenal ablative procedure during the course of the study. 4. Have a documented estimated glomerular filtration rate \< 45 mL/min/1.73 m2. 5. Have a planned dialysis, kidney transplantation or any major surgical procedure during the course of the study. 6. Have known documented New York Heart Association class III or IV chronic heart failure. 7. Have had a stroke, transient ischemic attack, hypertensive encephalopathy, acute coronary syndrome, or hospitalization for heart failure within 6 months before the Screening Visit. 8. Have known current severe left ventricular outflow obstruction. 9. Have had major cardiac surgery within 6 months before the Screening Visit. 10. Have a history of, or currently experiencing, clinically significant arrhythmias. 11. Have had a prior solid organ transplant or cell transplant. 12. Are positive for HIV antibody, hepatitis C virus RNA, or hepatitis B surface antigen. 13. Have typical consumption of \> 14 alcoholic drinks weekly.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hyperaldosteronism are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Greenbrae, California, 94904, United States
-
Research Site
San Francisco, California, 94110, United States
-
Research Site
West Hollywood, California, 90048, United States
-
Research Site
Chicago, Illinois, 60611, United States
-
Research Site
Baltimore, Maryland, 21287, United States
-
Research Site
Ann Arbor, Michigan, 48109, United States
-
Research Site
Rochester, Minnesota, 55905, United States
-
Research Site
Cincinnati, Ohio, 45245, United States
-
Research Site
Columbus, Ohio, 43210, United States
-
Research Site
Dallas, Texas, 75390-9047, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive tracer scan could replace invasive test for Hormone-Driven high blood pressure
- Can a pill quiet the adrenal Glands' hormone overdrive?
- Sauna bathing may offer a sweat-based path to lower blood pressure
- Can a new PET scan light up hidden adrenal tumors causing high blood pressure?
- Wearable tech puts hormone health to the test
- New scan could replace risky vein test for Hormone-Driven high blood pressure